Pharmacodynamic Properties of CJ-12420 on Evening Dosing

NCT03043521 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Dexlansoprazole 60 MG
DRUG: CJ-12420 50mg
DRUG: CJ-12420 100mg
DRUG: CJ-12420 200mg

Sponsor

HK inno.N Corporation